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The collagenase production of cultured skin fibroblasts from 
Scandinavian families with dommant (D-EED) and recessive 
(R-EED) epidermolysis bullosa dymophica has been investi-
gated. H eterogeneity as a result of body location origin has 
been ruled out as fibroblasts obtained from predilecrion sites 
produce the same amount of immunoreactive collagenase as 
those obtained from non-predilection sites of the same sub-
jects. Large variations in in vitro collagenase production were 
T he hereditary and acquired forms of the disease epi-dermolysis bullosa (EB) are characterized by bliS[cr formation of the skin in respons~ to minor mechanical trauma. Based on clinical and genetic studi~s. this dis-ease can be divided into at l~ast 16 subtypes [t]o In 
dystrophic EB. the blister formation occurs within the papillary 
dermis. and both recessive (R-EBD) and dominant (O-EBO) varie-
ties exisr [2}. Clinical heterogeneity both wirhin and between rhese 
groups exists. Some dominant forms are difficult to distinguish 
from localized r~cessive forms. R-EBD has been associated with 
dissolution of collagen fibrils [3.4] and changes in anchoring fibrils 
[4-6]. O-EBD has changes mainly in anchoring fibrils without 
collage no lysis [6-9J. The use of monoclonal antibodies raised 
against basement membrane components has also revealed antigen 
changes in R-EBD, but less so in D-EBD [10- 12]' One of these 
antibodies has been shown to react with type Vll collagen [13J, 
which form the anchoring fibrils [14J. Skin explants from R-EBD 
pa ti~nts contained an increased amount of collagenase activity com-
pared to skin from healthy control persons [15]' This increased 
activi ty seemed to be a result of an increased production ofimmuno-
reactive collagenase protein [16}. Cultured fibroblasts from eight of 
ten R-EBD patients also showed an increased collagenase activity 
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found between individuals and families. Within the R-EBD 
group. four out of eighteen patients showed an in vitro ele-
vated level of immunoreactive collagenase compared to rheir 
healrhy relatives, other EE types, and the control group. This 
shows rhatan in vitro elevated collagenase production is not a 
marker for the entire disease group and that the disease de-
noted as R-EED probably is etiologically and pathogeneti-
cally heterogeneous. J [IIVCS/ DermalOi 92:82 - 85, 1989 
and production of immunoreactive collagenase [171' as a result of 
either an increased concentration or enhanced trans arion of colla-
genase mRNA [18J. In cultured skin fibroblasts from rwo Finnish 
R-EBD patients there was no increase in total collar-enase activity. 
but an increased preactivation of the proenzyme {t 9 . In addition to 
an increased amount of collagenase in blister fluids from R-EBD 
patiems. increased amounts of serine and neutral thiol proteases 
have been reported [20.21], Phenytoin and other drugs known to 
regulate the collagenase synthesis in skin ~xplanrs and cultured fi-
broblasts [22J have been shown to be of therapeutic value in the 
trearmem of R-EBD patients [23.24,25] indicating that regulation 
of collagenase synthesis may be of pathogenetic importance for the 
disease. 
To determine whether increased collagenase production is a uni-
form marker for the R-EBO group. cultured fibroblasts from well-
characterized Scandinavian R-EBD kindreds were investigated. 
The possible existence of clonal heterogeneity of the skin fibroblast 
collagenase production as a result of the body location of the biopsy 
was also examined, In addition to individual differences in colla-
genase production. differences might also exist between families. 
Hence. unaffected members of the families were included, Ln each 
case collagenase production of cultured R-EBD fibroblasts was 
compared to that of fibroblasts from other EB types. other diseases. 
and healthy individuals. 
MATERIALS AND METHODS 
Subjects Skin fibroblasc cultures were established from biopsies 
taken from the medial or lateral aspect of upper arms, The subjects 
ex~mined were 5 Swedish (SEB). 25 Norwegian (EB). a.nd 2 Dutch 
(NEB) epidermolysis bullosa patients, 20 of their healthy relatives, 
and 11 other individuals serving as controls. 
The H.-EnD group includes three patients with the inverse-dys-
trophic type (R-EBD-I); eight patients (including twO sisters) with 
generalized dystrophic EB. the mutilans variety of recessive-EBD 
Hallopeau-Siemcns (R-EBD-HS); and four patients with local 
R-EBD-HS. Three other patients were characterized as R-EBD 
(gcncralized non-murilans) as they showed the same e1ectronmi-
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croscopic changes in both anchoring fibrils and collagen fibrils as all 
the former R-EBD-I and R-EBD-HS patients (Anton-Lamprecht. 
personal communication). Most of these 18 patients have previously 
been described both clinically and electronnucroscopically 11.4.26-
28J. 
The six dominant dystrophic cases showed changes in anchoring 
fibrils only 18.9; Anton-Lamprecht. personal communicationJ and 
belong to three families containing two to three affected genera-
tions each. 
One fetus had junctional Ell (R-EnJ) with a hemidesmosomc 
defect; 2 brothers had a new recessive pseudojunctional intraepider-
mal Ell; one patient had a severe dominant herpetiform Dowling-
Meara type (D-EBH-DM); one patient had the dominant general-
ized Kobner type; and three patients the dominant localized 
Weber-Cockayne cype of EB Simplex. 
To study potential heterogeneity among fibroblasts, skin cultures 
were enablished from biopsies taken from medial or lateral aspects 
of upper arms, knees, and trunk in the same individuals. The sub-
jeccs included cwo hcalchy persons (EB28-87, EB92-3), cwo 
D-EBD paciencs (EB28-1, EB92-4) , and one local R-EBD pacienc 
(EB 12-1). In the three EB patients, only the knee is a blister predi-
lection site. 
Fibroblast Cultures Cells from the established skin fibroblast 
cultures (some stored frozen) were subcultivated at passages 3 - 6 in 
disposable plastic culture dishes or flasks in Dulbecco's modified 
Eagle's medium (DMEM) containing 15% fetal calf serum, 30 mM 
N-2-hydroxyethylpipcrazine-N'-2-ethanesulfonic acid (HEPES) 
buffer (pH 7.2- 7.4), 100 IU/ ml penicillin, 100 pg/ml screpcomy-
cin. nonessential amino acids (100 times dilution). and 2.0 rnM 
L-glutamine at 37°C in a 95% 02: 5% CO2 atmosphere. 
To determine the collagenase expression. the cell cultures were 
grown to confluence in serum containing medium under rigorously 
controlled conditions [29,30}. The cell layer was washed 3- 4 times 
with Hank's balanced salt solution and then serum-free DMEM was 
added to the culture flask . After a 24-h incubation the serum-free 
medium was harvested and made 5 and 50 mM with respect to 
CaCl2 and Tris-HCL (pH 7.5). This solution was then used to 
determine the amount of immunoreactive collagenase protein. 
Im munoreactive Collagenase To determine the amOunt of im-
munoreactive collagenase protein, the previously reported enzyrne-
linked illll1lunosorbcnt assay (ELISA) was used [31). Human skin 
collagenase was purified according to earlier established methods 
132J and then used to develop the standard curves. 
RESULTS 
The influence of site of biopsy for the in vitro collagenase level was 
examined (Fig 1) . No difference between uPJer arms, knee. and 
lower back in the same individual was obtaine • suggesting that the 
specific levels within the individual subject could be used reliably. 
The pooled results of immunoreactive collagenase show that the 
fibroblast cultures from the R-EBD patients produce an increased 
amount of collagenase compared to the control group (Table I). 
Unaffected parents of the. R-EBD patients (obligate heterozygotes 
with respect to the Ell gene) and healthy siblings of the H.-EED 
patients (2/3 will be carriers) could not be distinguished from the 
conrrol group. The D-EBD group and other EB's were significantly 
lower than either the R-EED patients or the control group. 
These pooled results of the H.-EBD group do not give a true 
picture of the collagenase production within this group, however. 
because significant heterogeneity was found. Out of 18 R-EnD 
patients tested, there were four with a high collagenase production 
compared to the control group and their unaffected relatives. The 
collagenase production (mean ± SE) for these four individuals was 
EB 104-1 (R-EBD-I), 9.33 ± 2.36 pg/ml: EB V-I (R-EBD-I), 
5.91 ± 3.34 pg/ ml: EB 79-1 (R-EBD-HS), 6.16 ± 0.90 pg/ ml, 
and EB 10-1 (R-EBD-HS), 5.53 ± 0.96 ,Ug/ml. The cell culcures 
from the other 14 H.-EBD patients show a collagenase production of 
1.18 ± 0.21 I'g/ml (mean ± SE), which was equal co che D-EBD 
patients bur lower than the comrol group. When collagenase pro-
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Figure 1. The quantitation ofimmunoreactivc col lagenase (mean±SE) in 
cultured skin lihroblast srrainsobtained from different body sites. The biopsy 
sil ts were upper :arm (U2). knee (k), and back (b). The mau=rial contains two 
heahhy controls (EB 92-3and EB 28-87), twO D-EBD patients (EB 92-4 
and ED 28 - 1). and one R-EBD patient (ED 12 - 1). 
duction was examined within and berween kind reds, we found chat 
there were both inter- and intra-familial variations (Figs 1 and 2). In 
addition to rhe kind reds depicted in Figs 1 and 2, the cultured cells 
from one patient (SEE 13-1) showed collagenase expression within 
the range of control cultures, but nevertheless the production was 
six times greater than that of his father'S cells. Two other R-EBD 
patients had collagenase values that were higher than the control 
group (2.46 ± 1.00 pg/ ml; p > 0.05 and 2.76 ± 0.46 pg/ml; 
p < 0.05). However, a similar collagenase level of 2.06 ± 0.49 
Jig/ ml was found in the unaffected brother of one patient, while the 
collagenase level spanned from 2.1 to 4.1 ,ug/ml in cell cuh:ures 
from two healthy brothers and both parents of the other patient. 
These results suggest that the cell cultures from these two patients 
cannot absolutely be regarded as increased in collagenase produc-
tion. Finally, two of the 45 non-R-EBD fibroblast lines (both from 
non-ED families) showed high collagenase production, IR 42-5. 
6.63 ± 2.42 Jlg/ ml, and NF 3-121,4.51 ± 0.52pg/ml. Taking all 
findings together. these data suggest that it may be important to 
probe for regulatory mechanisms controlling collagenase synthesis 
within kindreds. 
DISCUSSION 
Previously it has been shown that blistered skin from patients with 
both R-EBD, R-EBJ, and D-EBD had an elevaced (in vivo) amounc 
of immunoreactive collagenase: compared to their unaffected skin 
and skin from healthy comrols [16J. Although selective increase in 
immunoreactive collagenase was seen in recessive junctional and 
dominant dystrophic EB. only R-EBD/atients had significantly 
elevated collagenase levels in unblistere skin [16]. in the present 
Table I. Production of Immunoreactive ColJagenase by 
Cultured Fibroblast Strains. 
Immunoreactive 
Num~ror Col lagenase 
Culture C ultures (pgfml)' p 
Controls (N=II) 18 1.92 ± 0.44 
R-EBD (N-18) 31 2.41 ± 0.46 <0.01 
Unaffected parents. obligate 18 1.70 ± 0.27 NS' 
heterozygotes (N=13) 
Unaffected siblings (N""'?) 7 1.85 ± 0.49 NS' 
D-EBD (N-6) 12 1.24 ± 0.25 <om 
Oth .. E.B. (N-8) 9 1.51 ± 0.34 <0.05 
• wh~n mot~ than on~ culrur~ was examm~d m one subject. thLS mdividual is repre-
sented In the total mean by the avenge of these cultures. 
• Expresscd ;as mean ± SE. 
• NS: nOt signific~n t . 
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Figure 2. The 9U:allttt-aU0I1 or immunoreactive coll:agen:ase (mean ± SE) 
in cultured skm I1hrobbst str.t.in~ derived rrom three R-EOD r-anlllies. Both 
SEB20-1 and SEB31-l :are classified as mutilans varieties of R-EBD-HS. 
while EBI04-1 is a R-EBD-I variant. 
study or in vitro collagenase production of fibroblascs we have 
shown that fibroblasts from differene body locations express the 
same amount of enzyme, ruling out clonal diversity of fibroblasts as 
a cause for this variabiliry. 
Based on previous in vitro data [171, an increased synthesis of 
imlllunoreactive collagenase in fibroblast cultures from R-EBD pa-
tienes has been assumed to be a genetic characteristic of at least 80% 
of paticnts with this disease, i.e., this was not a uniform trait, because 
cells frolll tWO of the 10 patients did not exceed the cOl1trol level. 
Furthermore, a heterogcneity among R-EBD patients was to be 
expected when five of 17 patients did not respond on phenytoin 
both in vivo and in vitro 1241. In the presene smdy of Scandinavian 
Ell patients, only four (two R-EBD-I and twO R-EBD-HS) ofthe 18 
It-EBD patients had an e1cvated collagenase level, while the other 
14 were within the control range. This clearly demonstrates that an 
elevated concentration of collagenase cannot be regarded as a ge-
nctic trait in all R-EBD fibroblasts , bur does not rule out the possi-
bility that this in vitro biochcmical trait is of pathologic importance 
in a portion of the patients. If causally related to the disease, the 
increased level of collagenase should then behave as a recessive trait 
and co-segregate with the disease. In this respect it is noreworthy 
that the fibroblast cultures from both parents of Ell 104-1 (high in 
collagenase) synthesized a nonnal amount of collagenase (Fig 2). 
This indicates that an elevated collagenase level actually is a reces-
sive characteristic of cul tured fibroblasts. To corroborate this hy-
pothesis and to ascertain co-segregation with R-EBO, we have now 
started to study the complete families of those patiencs with a high 
in viero level of collagenase. 
Because of different defects in the regulation, synthesis and struc-
ture of the collagenase enzyme may lead to poorly controlled colla-
gen degradation. and the etiology of the R-EBD may comprise 
different biochemical defects. Indeed, rhe heterogeneity of patho-
genesis in clinically indiscnminablc patients remains onc of the 
major mysteries in H.-EBD. In four of the American R-EBD patients 
with an increased in vitro level of collagenase. biochemical charac-
terization has revealed ... structurally aberrant form of the enzyme 
[331. suggcS[ing murations in the collagenase (eLC) locus. A nor-
Illal amount of total coll2genasc 2ctivity was found in culturC'd fi-
broblasts frolll rwo Finnish R-EBD patients, but in contrast to the 
control group the majority of the enzyme was activated, suggesting 
thar preactiv:!tion of the latent enzyme could bc of etiological im-
portance [191. Recently it has been proposed that factors derived 
from macro phages and PMN's stimulate collagen2se production of 
R-EBD fibroblasts in an altered fashion, and hence could playa role 
in rhe disease 1341. This indicates that the in vitro collagenase ex-
pression of cultured fibroblasts does not necessarily reflect rhe in 
vivo level, although previous results on two R-EBD patiencs 
showed this [17] . 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
Seven of the present series of R-EBD patients were included in 
the rrevious in vivo S{udy and six had an elcvated level of collagen-
ase 16] . An elevated tissue level of collagenase is frequently not 
reAecred in the cultured fibroblasts because only one patient was 
high both in vivo and in vitro. A high in vivo, normaJ in vitro 
collagcnase level suggests that the Interaction of different cells in 
the skin such as fibroblasts/monocytes may be responsible for the 
elevated tissue level of [he enzyme. Hence the interaction of the 
skin fibroblasts with its surrounding stroma could be of prime im-
portance for the pathogenesis in many H.-EBD families. The single 
patient with normal levels of collagenase, both in vivo and in vitro, 
must somehow have an altered collagenase enzyme nonreactive to 
inhibitor(s}. The two control fibroblast strains with an elevated 
collagenase level were naturally not included in the previous in vivo 
study. Howcvcr, family studies will reveal whether a high in vitro 
collagenase expression has a different Cluse in R-EBD and non-It-
EIlD individuals. 
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